Literature DB >> 3840375

Effect of tamoxifen, a nonsteroidal antiestrogen, on phospholipid/calcium-dependent protein kinase and phosphorylation of its endogenous substrate proteins from the rat brain and ovary.

H D Su, G J Mazzei, W R Vogler, J F Kuo.   

Abstract

Antiestrogens (tamoxifen, clomiphene and nafoxidine) were found to inhibit phospholipid/Ca2+-dependent protein kinase (PL/Ca-PK, or protein kinase C), whereas estrogens (estradiol and diethylstilbesterol) and the weakly estrogenic chlorotrianisene were inactive. Kinetic analysis indicated that the antiestrogens inhibited PL/Ca-PK competitively with respect to phosphatidylserine (Ki = 16-27 microM), but non-competitively with Ca2+ (Ki = 14-30 microM). Tamoxifen, but not diethylstilbesterol, also inhibited the phospholipid/Ca2+-dependent phosphorylation of various endogenous proteins from the total, solubilized fraction of the rat brain and ovary. Myosin light chain kinase, a calmodulin/Ca2+-dependent class of protein kinase, was similarly inhibited by tamoxifen; the drug, however, was without effect on cyclic AMP-dependent and cyclic GMP-dependent protein kinases. It is suggested that PL/Ca-PK, by virtue of the hydrophobic interactions required for the enzyme activation, may represent a potential site of action for the lipophilic antiestrogens, in addition to the commonly recognized intracellular estrogen receptors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3840375     DOI: 10.1016/0006-2952(85)90225-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  23 in total

Review 1.  Review of pharmacological treatment in mood disorders and future directions for drug development.

Authors:  Xiaohua Li; Mark A Frye; Richard C Shelton
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

Review 2.  Endocrine therapy of metastatic breast cancer.

Authors:  A Manni
Journal:  J Endocrinol Invest       Date:  1989-05       Impact factor: 4.256

3.  Repurposing ospemifene for potentiating an antigen-specific immune response.

Authors:  Chiao-Jung Kao; Gregory T Wurz; Yi-Chen Lin; Daniel P Vang; Brian Phong; Michael W DeGregorio
Journal:  Menopause       Date:  2017-04       Impact factor: 2.953

Review 4.  Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer.

Authors:  H M Bryson; G L Plosker
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

5.  The effect of estrogen and tamoxifen on hepatocyte proliferation in vivo and in vitro.

Authors:  A Francavilla; L Polimeno; A DiLeo; M Barone; P Ove; M Coetzee; P Eagon; L Makowka; G Ambrosino; V Mazzaferro
Journal:  Hepatology       Date:  1989-04       Impact factor: 17.425

6.  Design and synthesis of triarylacrylonitrile analogues of tamoxifen with improved binding selectivity to protein kinase C.

Authors:  Colleen Carpenter; Roderick J Sorenson; Yafei Jin; Szymon Klossowski; Tomasz Cierpicki; Margaret Gnegy; Hollis D Showalter
Journal:  Bioorg Med Chem       Date:  2016-09-04       Impact factor: 3.641

Review 7.  Tamoxifen and amphetamine abuse: Are there therapeutic possibilities?

Authors:  Sarah Mikelman; Natalie Mardirossian; Margaret E Gnegy
Journal:  J Chem Neuroanat       Date:  2016-08-30       Impact factor: 3.052

8.  Direct and Systemic Administration of a CNS-Permeant Tamoxifen Analog Reduces Amphetamine-Induced Dopamine Release and Reinforcing Effects.

Authors:  Colleen Carpenter; Alexander G Zestos; Rachel Altshuler; Roderick J Sorenson; Bipasha Guptaroy; Hollis D Showalter; Robert T Kennedy; Emily Jutkiewicz; Margaret E Gnegy
Journal:  Neuropsychopharmacology       Date:  2017-05-11       Impact factor: 7.853

9.  Phorbol ester regulation of Ca2+ flux during natural, lectin and antibody-dependent killing.

Authors:  M Jondal; J Ng; M Patarroyo; P A Broliden
Journal:  Immunology       Date:  1986-11       Impact factor: 7.397

Review 10.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.